NEW YORK, Sept. 12 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, today announced that Stephen Beckman has joined the company in the new position of Vice President Sales & Marketing and Commercial Development. Mr. Beckman's responsibilities will include directing Inyx's new co- marketing relationship with King Pharmaceuticals, Inc. (NYSE:KG), under which Inyx will co-market King's Intal(R) and Tilade(R) respiratory products. Inyx's co-marketing of Intal(R) and Tilade(R) will be conducted by a newly established wholly owned Inyx subsidiary, Exaeris, Inc., which will be independent of the company's contract development and manufacturing operations. Jack Kachkar, M.D., Chairman and Chief Executive Officer of Inyx, Inc., said, "We are very pleased to have Steve Beckman, who has more than 15 years of sales and marketing experience in the respiratory products sector, join Inyx to manage our new co-marketing initiatives with King Pharmaceuticals as well as cultivate other new commercial business opportunities for Inyx." "I am very excited to join Inyx at this stage in the company's evolution. Inyx's expertise and technologies in aerosol drug delivery, particularly in inhalation therapy, are strategic niches on the threshold of material growth opportunities in today's marketplace," said Mr. Beckman. "Mr. Beckman has joined our company at a particularly auspicious time," Dr. Kachkar noted, "as we have commenced three 'transforming events' in Inyx's history within the past six months." On September 8, 2005, Inyx and King Pharmaceuticals announced that they have entered into a long-term, strategic alliance that represents Inyx's first revenue-sharing deal with a client. On August 31, 2005, Inyx announced completion of its strategic acquisition of Celltech Manufacturing Services Limited in Ashton, England (near Manchester), expanding Inyx's development and production capabilities as well as strengthening Inyx's abilities to serve the United Kingdom, Europe and Asia. On March 31, 2005, Inyx completed its acquisition of certain assets and business of Aventis Pharmaceuticals Puerto Rico Inc. from sanofi-aventis Group (NYSE:SNY), providing Inyx with a strategic operating base in the United States. Stephen Beckman Prior to joining Inyx, Mr. Beckman served as a consultant to the pharmaceutical industry. Earlier, he served as Corporate Vice President of Global Franchise Management and Vice President of Corporate Marketing, Respiratory for Altana Pharma AG. He also was Worldwide Director - Pulmonary Marketing for Smithkline Beecham Pharmaceuticals. Mr. Beckman has held executive marketing positions also with Astra Merck Corporation and Fisons Pharmaceuticals Corporation, and he began his career with Marion Merrell Dow Pharmaceuticals. Mr. Beckman holds a B.S. in Marketing from Syracuse University and graduate studies in pharmaceutical marketing from UCLA and advanced studies at the Wharton School of Business. About Inyx Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products to be marketed by selected clients and strategic partners. The company's operations are conducted through several wholly owned subsidiaries, including: Inyx USA, Ltd., based in Manati, Puerto Rico; Inyx Pharma Limited, near Manchester, England; Inyx Europe Limited, also near Manchester; and Inyx Canada, Inc. in Toronto. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit: http://www.inyxinc.com/. Safe Harbor Statements about Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Inyx intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results. For more information, please contact: Jay M. Green, Executive VP Inyx, Inc. 212-838-1111 DATASOURCE: Inyx, Inc. CONTACT: Jay M. Green, Executive VP of Inyx, Inc., +1-212-838-1111, Web site: http://www.inyxinc.com/

Copyright